Neurohumoral fluid regulation in chronic liver disease

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 58, Issue 5, 1998, Pages 361-372

  Moller S ^b   Henriksen, J H ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; CALCITONIN GENE RELATED PEPTIDE; NEUROHORMONE; NITRIC OXIDE; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

BLOOD VESSEL REACTIVITY; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FLUID BALANCE; HEMODYNAMICS; HUMAN; HYPOVOLEMIA; LIVER CIRRHOSIS; MULTIPLE ORGAN FAILURE; NEUROENDOCRINE SYSTEM; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM RETENTION; SPLANCHNIC BLOOD FLOW;

ADRENOMEDULLIN; BODY FLUIDS; CALCITONIN GENE-RELATED PEPTIDE; HEMODYNAMIC PROCESSES; HOMEOSTASIS; HUMANS; KIDNEY; LIVER DISEASES; NITRIC OXIDE; PEPTIDES; VASODILATOR AGENTS;

EID: 0031739307     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365519850186346     Document Type: Review

References (107)

1. Lieberman FL, Denison EK, Reynolds TB. The relationship of plasma volume, portal hypertension, ascites, and renal sodium retention in cirrhosis. The overflow theory of ascites formation. Ann NY Acad Sci 1970; 170: 202-12.
2. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral artery vasodilatation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 5: 1151-7.
3. Schrier RW, Niederberger M, Weigert A, Gines P. Peripheral arterial vasodilatation: determinant of functional spectrum of cirrhosis. Sem Liver Dis 1994; 14: 14-22.
4. Arroyo V, Gines P. Arteriolar vasodilatation and the pathogenesis of the hyperdynamic circulation and renal sodium and water retention in cirrhosis. Gastroenterology 1992; 102: 1077-9.
5. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991; 337: 776-8.
6. Groszmann RJ. Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences. Hepatology 1994; 20: 1359-63.
7. Gupta S, Morgan TR, Gordan GS. Calcitonin gene-related peptide in hepatorenal syndrome. J Clin Gastroenterol 1992; 14: 122-6.
8. Moore K, Wendon J, Frazer M, Karani J, Williams R, Badr K. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 1992; 327: 1774-8.
9. Lemoine O, Soupison T, Sogni P, Marchant A, Moreau R, Hadengue A, et al. Plasma endotoxin and tumor necrosis factor-alpha in the hyperkinetic state of cirrhosis. J Hepatol 1995; 23: 391-5.
10. Wong F, Blendis L. Natriuretic peptides: are these new links in the hepatorenal connections? Gut 1997; 40: 151-2.
11. Fernandez-Rodriguez CM, Prieto J, Quiroga J, Zozoya JM, Andrade A, Nunez M, et al. Plasma levels of substance P in liver cirrhosis: relationship to the activation of vasopressor systems and urinary sodium excretion. Hepatology 1995; 21: 35-40.
12. Moore K, Ward PS, Taylor GW, Williams R. Systemic and renal production of troboxane A2 and prostacyclin in decompensatd liver disease and hepatorenal syndrome. Gastroenterology 1991; 100: 1069-77.
13. Sieber CC, Lopez-Talavera JC, Groszmann RJ. Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats. Gastroenterology 1993; 104: 1750-4.
14. Pizcueta P, Pique JM, Fernandez M, Bosch J, Rodes J, Whittle BJR, et al. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology 1992; 103: 1909-15.
15. Sieber CC, Groszmann RJ. Nitric oxide mediates hyporeactivity to vasopressors in mesenteric vessels of portal hypertensive rats. Gastroenterology 1992; 103: 235-9.
16. Karatapanis S, Mccormick PA, Kakad S, Chin JKT, Islam M, Jeremy J, et al. Alteration in vascular reactivity in isolated aortic rings from portal vein-constricted rats. Hepatology 1994; 20: 1516-21.
17. Sogni P, Moreau R, Ohsuga M, Cailmail S, Oberti F, Hadengue A, et al. Evidence for normal nitric oxide mediated vasodilator tone in conscious rats with cirrhosis. Hepatology 1992; 16: 980-3.
18. Jones AL, Bangash IH, Bouchier IAD, Hayes PC. Portal and systemic haemodynamic action of N-acetylcysteine in patients with stable cirrhosis. Gut 1994; 35: 1290-3.
19. Lee F-Y, Colombato LA, Albillos A, Groszmann RJ. N-nitro-L-arginine administration corrects peripheral vasodilatation and systemic capillary hypotension and ameliorates plasma volume expansion and sodium retention in portal hypertensive rats. Hepatology 1993; 17: 84-90.
20. Niederberger M, Gines P, Martin PY, Tsai P, Morris K, McMurtry I, et al. Comparison of vascular nitric oxide production and systemic hemodynamics in cirrhosis versus prehepatic portal hypertension in rats. Hepatology 1996; 24: 947-51.
21. Kakumitsu S, Shijo H, Yokoyama M, Kim T, Akiyoshi N, Ota K, et al. Effects of L-arginine on the systemic, mesenteric, and hepatic circulation in patients with cirrhosis. Hepatology 1998; 27:377-82.
22. Söderman C, Leone A, Furst V, Persson MG. Endogenous nitric oxide in exhaled air from patients with liver cirrhosis. Scand J Gastroenterol 1997; 32: 591-7.
23. Rolla G, Brussino L, Colagrande P, Dutto L, Polizzi S, Scappaticci E, et al. Exhaled nitric oxide and oxygenation abnormalities in hepatic cirrhosis. Hepatology 1997; 26: 842-7.
24. Calver A, Harris A, Maxwell JD, Vallance P. Effect of local inhibition of nitric oxide synthesis on forearm blood now and dorsal hand vein size in patients with alcoholic cirrhosis. Clin Sci 1994; 86: 203-8.
25. Ryan J, Jennings G, Dudley F, Chindusting J. Smooth muscle-derived nitric oxide is elevated in isolated forearm veins in human alcoholic cirrhosis. Clin Sci 1996; 91: 23-8.
26. Fernandez M, Garcia-Pagan JC, Casadevall M, Bernadich C, Piera C, Whittle BJR, et al. Evidence against a role for inducible nitric oxide synthase in the hyperdynamic circulation of portal-hypertensive rats. Gastroenterology 1995; 108: 1487-95.
27. Kanwar S, Kubes P, Tepperman BL, Lee SS. Nitric oxide synthase activity in portal-hypertensive and cirrhotic rats. J Hepatol 1996; 25: 85-9.
28. Bomzon A, Blendis LM. The nitric oxide hypothesis and the hyperdynamic circulation in cirrhosis. Hepatology 1994; 20: 1343-50.
29. Campillo B, Chabrier PE, Pelle G, Sediame S, Atlan G, Fouet P, et al. Inhibition of nitric oxide synthesis in the forearm arterial bed of patients with advanced cirrhosis. Hepatology 1995; 22: 1423-9.
30. O'Halloran DJ, Bloom SR. Calcitonin gene-related peptide. A major neuropeptide and the most powerful vasodilator known. Br Med J 1991; 302: 739-40.
31. Bendtsen F, Schifter S, Henriksen JH. Increased circulating calcitonin gene-related peptide (CGRP) in cirrhosis. J Hepatol 1991; 12: 118-23.
32. McNicol PL, Liu G, Shulkes A, Hardy KJ, Jones RM. Vasoactive intestinal peptide and calcitonin gene-related peptide levels and hemodynamics during human liver transplantation. Transplant Proc 1993; 25: 1830-1.
33. Møller S, Becker U, Schifter S, Abrahamsen J, Henriksen JH. Effect of oxygen inhalation on systemic, central, and splanchnic haemodynamics in cirrhosis. J Hepatol 1996; 25: 316-28.
34. Møller S, Bendtsen F, Schifter S, Henriksen JH. Relation of calcitonin gene-related peptide to systemic vasodilatation and central hypovolacmia in cirrhosis. Scand J Gastroenterol 1996; 31: 928-33.
35. Hori N, Okanoue T, Sawa Y, Kashima K. Role of calcitonin gene-related peptide in the vascular system on the development of the hyperdynamic circulation in conscious cirrhotic rats. J Hepatol 1997; 26: 1111-19.
36. Richards AM, Nicholls MG, Lewis L, Lainchbury JG. Adrenomedullin. Clin Sci 1996; 91: 3-16.
37. Cheung B, Leung R. Elevated plasma levels of human adrenomedullin in cardiovascular, respiratory, hepatic and renal disorders. Clin Sci 1997; 92: 59-62.
38. Guevara M, Gines P, Jimenez W, Sort P, Fernandezesparrach G, Escorsell A, et al. Increased adrenomedullin levels in cirrhosis: relationship with hemodynamic abnormalities and vasoconstrictor systems. Gastroenterology 1998; 114: 336-43.
39. Groszmann RJ. Vasodilatation and hyperdynamic circulatory state in chronic liver disease. In: Bosch J, Groszmann RJ, editors. Portal hypertension. Pathophysiology and treatment. Oxford: Blackwell 1994: 17-26.
40. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351: 9-13.
41. Bernardi M, Trevisani F, Gasbarrini A, Gasbarrini G. Hepatorenal disorders. Role of the renin - angiotensin - aldosterone system. Sem Liver Dis 1994; 14: 23-34.
42. Henriksen JH, Ring-Larsen H. Hepatorenal disorders: role of the sympathetic nervous system. Sem Liver Dis 1994; 14: 35-43.
43. Arroyo V, Claria J, Salo J, Jimenez W. Antidiuretic hormone and the pathogenesis of water retention in cirrhosis with ascites. Sem Liver Dis 1994; 14: 44-58.
44. Møller S, Henriksen JH. Endothelins in chronic liver disease. Scand J Clin Lab Invest 1996; 56: 481-90.
45. Rocky D. The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide. Hepatology 1997; 25: 2-5.
46. Lee SS. Cardiac abnormalities in liver cirrhosis. West J Med 1989; 151: 530-5.
47. Ma Z, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology 1996; 24: 451-9.
48. Henriksen JH, Bendtsen F, Sørensen TIA, Stadeager C, Ring-Larsen H. Reduced central blood volume in cirrhosis. Gastroenterology 1989; 97: 1506-13.
49. Dudley FJ. Pathophysiology of sodium retention in cirrhosis. In: Bosch J, Groszmann RJ, editors. Portal hypertension. Pathophysiology and treatment. Oxford: Blackwell, 1994: 54-71.
50. Bomzon A, Binah O, Blendis LM. Hypotension in experimental cirrhosis - Is loss of vascular responsiveness to norepinephrine the cause of hypotension in chronic bile-duct-ligated dogs. J Hepatol 1993; 17: 116-23.
51. Bernardi M, Rubboli A, Trevisani F, Cancellieri C, Ligabue A, Baradini M, et al. Reduced cardiovascular responsiveness to exercise-induced sympathoadrenergic stimulation in patients with cirrhosis. J Hepatol 1991; 12: 207-16.
52. MacGilchrist AJ, Sumner D, Reid JL. Impaired pressor reactivity in cirrhosis: evidence for a peripheral vascular defect. Hepatology 1991; 13: 689-94.
53. Dillon JF, Plevris JN, Nolan J, Ewing DJ, Neilson JMM, Bouchier IAD, et al. Autonomic function in cirrhosis assessed by cardiovascular reflex tests and 24-hour heart rate variability. Am J Gastroenterol 1994; 89: 1544-7.
54. Murray BM, Paller MS. Decreased pressor reactivity to angiotensin II in cirrhotic rats. Evidence for a post-receptor defect in angiotensin action. Circ Res 1985; 57: 424-31.
55. Polio J, Sieber CC, Lerner E, Groszmann RJ. Cardiovascular hyporesponsiveness to norepinephrine, propranolol and nitroglycerin in portal-hypertensive and aged rats. Hepatology 1993; 18: 128-36.
56. Gerbes AL, Remien J, Jüngst D, Sauerbruch T, Paumgartner G. Evidence for down-regulation of bcta-2-adrenoceptors in cirrhotic patients with severe ascites. Lancet 1986; 1: 1409-11.
57. Bierbrier GS, Adams PC, Feldman RD. Vascular alpha-adrenergic responsiveness is reduced in cirrhosis. Clin Pharmacol Ther 1994; 56: 668-71.
58. Moreau R, Komaichi H, Kistetter P, Ohsuga M, Cailmail S, Lebrec D. Altered control of vascular tone by adenosine triphosphate-sensitive potassium channels in rats with cirrhosis. Gastroenterology 1994; 106: 1016-23.
59. Chu CJ, Lee FY, Wang SS, Lu RH, Tsai YT, Lin HC, et al. Hyperdynamic circulation of cirrhotic rats with ascites: role of endotoxin, tumour necrosis factor-alpha and nitric oxide. Clin Sci 1997; 93: 216-25.
60. Lopez-Talavera JC, Merrill WW, Groszmann RJ. Tumor necrosis factor alpha: a major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology 1995; 108: 761-7.
61. Moreau R, Lebrec D. Endogenous factors involved in the control of arterial tone in cirrhosis. J Hepatol 1995; 22: 370-6.
62. Hendrickse MT, Thuluvath PJ, Triger DR. Natural history of autonomic neuropathy in chronic liver disease. Lancet 1992; 339: 1462-4.
63. Laffi G, Lagi A, Cipriani M, Barletta G, Bernardi L, Fattorini L, et al. Impaired cardiovascular autonomic response to passive tilting in cirrhosis with ascites. Hepatology 1996; 24: 1063-7.
64. Oliver MI, Miralles R, Rubiesprat J, Navarro X, Espadaler JM, Sola R, et al. Autonomie dysfunction in patients with non-alcoholic chronic liver disease. J Hepatol 1997; 26: 1242-8.
65. Fleckenstein JF, Frank SM, Thuluvath PJ. Presence of autonomie neuropathy is a poor prognostic indicator in patients with advanced liver disease. Hepatology 1996; 23: 471-5.
66. Mohammed R, Forsey PR, Davies MK, Neuberger JM. Effect of liver transplantation on QT interval prolongation and autonomie dysfunction in end-stage liver disease. Hepatology 1996; 23: 1128-34.
67. Hendrickse MT, Triger DR. Vagal dysfunction and impaired urinary sodium and water excretion in cirrhosis. Am J Gastroenterol 1994; 89: 750-7.
68. Isobe H, Sakai H, Sakamoto S, Nawata H. Decreased variation of electrocardiographic RR interval in patients with liver cirrhosis. J Gastroenterol Hepatol 1994; 9: 232-5.
69. Laffi G, Barletta G, Lavilla G, Delbene R, Riccardi D, Ticali P, et al. Altered cardiovascular responsiveness to active tilting in nonalcoholic cirrhosis. Gastroenterology 1997; 113: 891-8.
70. Iwao T, Toyonaga A, Ikegami M, Sumino M, Oho K, Sakaki M, et al. Reduced portosystemic hemodynamic responsiveness after orthostasis in patients with cirrhosis. Dig Dis Sci 1993; 38: 1251-8.
71. Ryan J, Sudhir K, Jennings G, Esler M, Dudley F. Impaired reactivity of the peripheral vasculature to pressor agents in alcoholic cirrhosis. Gastroenterology 1993; 105: 1167-72.
72. Dillon JF, Nolan J, Thomas H, Williams BC, Neilson JMM, Bouchier IAD, et al. The correction of autonomie dysfunction in cirrhosis by captopril. J Hepatol 1997; 26: 331-5.
73. Lazzeri C, Lavilla G, Laffi G, Vecchiarino S, Gambilonghi F, Gentilini P, et al. Autonomic regulation of heart rate and QT interval in non-alcoholic cirrhosis with ascites. Digestion 1997; 58: 580-6.
74. Bernardi M, Calandra S, Colantoni A, Trevisani F, Raimondo ML, Sica G, et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 1998; 27: 28-34.
75. Lee SS, Pak JM, Medlicott SM, Bomzon A. Vasodilatory responses of isolated arteries of cirrhotic rats. Clin Sci 1995; 89: 227-32.
76. Jaue DN, Ma ZH, Lee SS. Cardiac muscarinic receptor function in rats with cirrhotic cardiomyopathy. Hepatology 1997; 25: 1361-5.
77. Rowell LB. Human cardiovascular control. Oxford: Oxford University Press, 1993.
78. Kumada M, Terui N, Kuwaki T. Arterial baroreceptor reflex: its central and peripheral neural mechanisms. Progr Neurobiol 1990; 35: 331-61.
79. Schrier RW, Howard RL. Unifying hypothesis of sodium and water regulation in health and disease. Hypertension 1991; 18 Suppl III: 164-8.
80. Henriksen JH, Ring-Larsen H, Christensen NJ. Sympathetic nervous regulation in patients with cirrhosis: pathogenesis of fluid retention and formation of ascites. Can J Gastroenterol 1991; 5(3): 103-11.
81. Kirstetter P, Moreau R, Soupison T, Cailmail S, Hartleb M, Lebrec D. Role of sympathetic cardiovascular tone in control of arterial pressure in rats with cirrhosis. Liver 1996; 16: 263-6.
82. Møller S, Emmeluth C, Henriksen JH. Elevated circulating plasma endothelin - 1 concentrations in cirrhosis. J Hepatol 1993; 19: 285-90.
83. Møller S, Wiinberg N, Henriksen JH. Noninvasive 24-hour ambulatory arterial blood pressure monitoring in cirrhosis. Hepatology 1995; 22: 88-95.
84. Pasqualetti P, Festuccia V, Collacciani A, Acitelli P, Casale R. Circadian rhythm of arginine vasopressin in hepatorenal syndrome. Nephron 1998; 78: 33-7.
85. Trevisani F, Colantoni A, Gerbes AL, Gülberg V, Sica G, Caraceni P, et al. Daily profile of plasma endothelin-1 and -3 in pre-ascitic cirrhosis: relationships with the arterial pressure and renal function. J Hepatol 1997; 26: 808-15.
86. Møller S, Christensen E, Henriksen JH. Continuous blood pressure monitoring in cirrhosis: relations to systemic and splanchnic haemodynamics. J Hepatol 1997; 27: 284-94.
87. Møller S, Bendtsen F, Christensen E, Henriksen JH. Prognostic variables in patients with cirrhosis and oesophageal varices without prior bleeding. J Hepatol 1994; 21: 940-6.
88. Møller S, Søndergaard L, Møgelvang J, Henriksen O, Henriksen JH. Decreased right heart blood volume determined by magnetic resonance imaging: evidence of central underfilling in cirrhosis. Hepatology 1995; 22: 472-8.
89. Møller S. Systemic haemodynamics in cirrhosis and portal hypertension with focus on vasoactive substances and prognosis. Dan Med Bull 1998; 45: 1-14.
90. Møller S, Bendtsen F, Henriksen JH. Effect of volume expansion on systemic hemodynamics and central and arterial blood volume in cirrhosis. Gastroenterology 1995; 109: 1917-25.
91. Colombato LA, Albillos A, Groszmann J. The role of central blood volume in the development of sodium retention in portal hypertensive rats. Gastroenterology 1996; 110: 193-8.
92. Laffi G, La Villa G, Gentilini P. Pathogenesis and management of the hepatorenal syndrome. Sem Liver Dis 1994; 14: 1-81.
93. Henriksen JH, Bendtsen F, Gerbes AL, Christensen NJ, Ring-Larsen H, Sørensen TIA. Estimated central blood volume in cirrhosis -relationship to sympathetic nervous activity, beta-adrenergic blockade and atrial natriuretic factor. Hepatology 1992; 16: 1163-70.
94. Wong F, Liu P, Blendis L. Assessment of central blood volume in cirrhosis by radionuclide angiography: What does it really mean? Reply. Hepatology 1994; 20: 1654-6.
95. Blendis LM. Circulation in liver disease. Transplant Proc 1993; 25: 1741-3.
96. Gaudin C, Braillon A, Poo JL, Moreau R, Hadengue A, Lebrec D. Regional sympathetic activity, severity of liver disease and hemodynamics in patients with cirrhosis. J Hepatol 1991; 13: 161-8.
97. Brinch K, Møller S, Bendtsen F, Henriksen JH. Effect of albumin-induced volume expansion on central- and non-central blood volumes in cirrhosis. J Hepatol 1997; 26 Suppl 1: 99.
98. Salerno F, DelBo A, Maggi A, Marabini M, Maffi M, Borroni GM, et al. Vasopressin release and water metabolism in patients with cirrhosis. J Hepatol 1994; 21: 822-30.
99. Henriksen JH, Ring-Larsen H. Ascites formation in liver cirrhosis: the how and the why. Dig Dis Sci 1990; 8: 152-62.
100. Hayes PC, Cumming AD, Craig KJ, Watson M, Bouchier IAD. Portal and systemic hemodynamics and humoral factors in cirrhosis with and without ascites. Am J Gastroenterol 1992; 87: 1433-8.
101. Henriksen JH, Ring-Larsen H. Raised renal venous pressure: direct cause of renal sodium retention in cirrhosis? Lancet 1988; ii: 8602.
102. Henriksen JH, Ring-Larsen H. Renal effects of drugs used in the treatment of portal hypertension. Hepatology 1993; 18: 688-95.
103. Nicholls KM, Shapiro MD, Kluge R. Sodium excretion in advanced cirrhosis: effect of expansion of central blood volume and suppression of plasma aldosterone. Hepatology 1986; 82: 709-19.
104. Lenz K, Hörtnagel H, Druml W, Reiter H, Schmid R, Schneeweiss B, et al. Omnipressin in the treatment of functional renal failure in decompensated cirrhosis: effects on renal hemodynamics and atrial natriuretic factor. Gastrocnterology 1991; 101: 1060-7.
105. Guevara M, Gines P, Fernandez-Esparrach G, Sort P, Salmeron JM, Jimenez W, et al. Reversibility of hepatorenal syndrome by prolonged administration of omnipressin and plasma volume expansion. Hepatology 1998; 27: 35-41.
106. Forrest EH, Bouchier IAD, Hayes PC. Acute effect of low dose theophylline on the circulatory disturbances of cirrhosis. Gut 1997; 40: 139-44.
107. Haynes WG, Ferro CJ, Okane KPJ, Somerville D, Lomax CC, Webb DJ. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 1996; 93: 1860-70.